No material corporate briefing disclosures were identified for Merck & Co. in the period immediately preceding this report's generation date of 2026-06-01. The report was triggered by material institutional position changes observed in recent 13F filings, as detailed in the holdings section below [Brief - 2026-05-24].
For the trailing twelve months ending 2026-03-31, Merck reported revenue of $65.77 billion, representing year-over-year growth of 4.87%. Net income over the same period was $8.94 billion, yielding a net margin of 13.59%. Operating margin stood at 0.56%. EPS declined 185.57% year-over-year on a TTM basis. The company held $5.33 billion in cash against total debt of $49.12 billion. The price-to-earnings ratio was recorded at 33.44 [SEC 10-Q - MRK - 2026-03-31].
Insider activity recorded four transactions in the most recent 30-day period, with a mixed net direction and a net aggregate value of zero, indicating no material net accumulation or disposal among reporting insiders [SEC Form 4 - MRK - 2026-06]. At the institutional level, three significant position reductions were filed: Citadel reduced its MRK position by 7%, AQR Capital reduced its position by 23%, and Millennium reduced its position by 55% [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Millennium - Q1 2026].
The prevailing macro environment reflects a normal yield curve, with the 10-year US Treasury yield at 4.45% and the 2-year yield at 3.99% as of the report date [FRED DGS10] [FRED DGS2]. The 46-basis-point spread between the two tenors represents a positive term premium, a configuration that has historically accompanied varied conditions across large-cap pharmaceutical equities.